https://www.europesays.com/1627072/ Science 37 Nearly Doubles U.S. Enrollment for GSK Phase 3 #america #ClinicalResearch #ClinicalStudy #ClinicalTrialAccess #ClinicalTrialEnrollment #ClinicalTrials #Inc. #Nasdaq:SNCE #science #Science37 #technology #UnitedStates #UnitedStatesOfAmerica #US #USA
An international research team has developed a new treatment approach for severe COVID-19, potentially enabling faster recovery and reduced mortality. Results from the Phase II study show that the FasL inhibitor Asunercept allows recovery in an average of 8 days—compared to 13 days in the control group. 
Read more 
https://uni.koeln/V3TPT
https://www.sciencedirect.com/science/article/pii/S2589537024004589?via%3Dihub
L’université de Maastricht recherche des volontaires pour étudier l’influence de la psilocybine sur la douleur ressentie par les personnes atteintes de fibromyalgie !
